Sentara Cardiovascular Research Institute
Over the last decade, SCRI cardiologists and uniquely trained registered nurse research coordinators have made significant strides in advancing the understanding and treatment of the No. 1 killer in America: Cardiovascular disease.
As the pre-eminent cardiac research institute in the Mid-Atlantic region, Sentara Heart works collaboratively with local institutions, government agencies and biomedical companies on nationally and internationally recognized clinical research trials. We focus our efforts on discovering more effective cardiovascular treatments and protocols while eliminating those that are potentially harmful or not as beneficial. Our ultimate goal is to provide enhanced clinical care that advances patient outcomes and improves the overall health of our community.
Our research touches on every aspect of heart care, including medical devices, heart failure, electrophysiology, cardiac surgery, cardiac interventional procedures, structural heart disease, and the medical management of coronary artery disease risk factors such as diabetes and high cholesterol.
Collectively, our research nurses coordinate more than 80 clinical trials at any given time, shepherding participants through the entire trial process, providing care during periods of need, and tirelessly advocating for their patients’ well-being.
Investigational Research Studies at Sentara Heart
Here is a sampling of some of the clinical trials active at SCRI in 2015.
Michael Eggert, MD
To assess the efficacy and safety of oral beraprost-314d-MR added-on to inhaled treprostinil (BEAT) in subjects with pulmonary arterial hypertension.
John Herre, MD
To compare the effects of bucindolol hydrochloride to metoprolol succinate (Toprol-XL) on the recurrence of symptomatic atrial fibrillation/atrial flutter in patients with heart failure who have a specific genotype for the beta-1 adrenergic receptor.
Paul Mahoney, MD, and
Joseph Newton, MD
To investigate the safety and efficacy of transcatheter aortic valve implantation (TAVI) in patients with severe, symptomatic aortic stenosis at intermediate surgical risk by randomizing patients to either surgical aortic valve replacement (SAVR) or TAVI with the Medtronic CoreValve® System.
Michael McGrath, MD
To evaluate the safety and effectiveness of the HeartMate 3 left ventricular assist device (LVAS) by demonstrating non-inferiority to the HeartMate 2 LVAS when used for the treatment of advanced, refractory, left ventricular heart failure.
Jonathan Philpott, MD
To establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure (DEEP) for patients presenting with persistent atrial fibrillation or longstanding persistent atrial fibrillation.
Resolute Integrity Long Lesion
Ronald McKechnie, MD
To conduct a prospective, multi-center evaluation of the procedural and clinical outcomes of subjects who are treated with the commercially available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System.